Chia Ling Wang

Director/Board Member presso UNITED BIOPHARMA INC

72 anni

Consumer Services

Producer Manufacturing

Health Technology

Profilo

Jia Ling Wang is currently a Director at Shanghai Baolong Automotive Corp., an Independent Director at United BioPharma, Inc., and a Professor at The Hong Kong University of Science & Technology.
Previously, Ms. Wang served as an Independent Non-Executive Director at Television Broadcasts Ltd.
from 2015 to 2021.
Ms. Wang received a graduate degree from Harvard University in 1977, an undergraduate degree from National Taiwan University in 1974, and a graduate degree from the University of Wisconsin-Milwaukee in 1976.

Posizioni attive di Chia Ling Wang

Società	Posizione	Inizio
UNITED BIOPHARMA INC	Director/Board Member	30/09/2014
SHANGHAI BAOLONG AUTOMOTIVE CORPORATION	Director/Board Member	01/01/2014
The Hong Kong University of Science & Technology	Corporate Officer/Principal	-

Tutte le posizioni attive di Chia Ling Wang

Precedenti posizioni note di Chia Ling Wang

Società	Posizione	Fine
TELEVISION BROADCASTS LIMITED	Director/Board Member	26/05/2021

Vedi nel dettaglio l'esperienza di Chia Ling Wang

Formazione di Chia Ling Wang

Harvard University	Graduate Degree
National Taiwan University	Undergraduate Degree
University of Wisconsin-Milwaukee	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Chia Ling Wang

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
TELEVISION BROADCASTS LIMITED	Consumer Services
SHANGHAI BAOLONG AUTOMOTIVE CORPORATION	Producer Manufacturing

Aziende private	1
United BioPharma, Inc. United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan.	Health Technology